Notice: Get a jump on 2015 — Pay your 2015 ASA membership dues now!

>

MEETINGS / EVENTS

RSS

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit

>

FDA MEDWATCH ALERTS

December 18, 2014

0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter

Summary:

FDA MedWatch Recall - Particulate Matter

November 21, 2014

FDA MedWatch - Respironics California, Esprit V1000 and V200 Ventilators: Class I Recall - Power Failure May Occur

Summary:

FDA MedWatch Respironics California Esprit V1000 and V200 Ventilators Class I Recall

November 21, 2014

FDA MedWatch - Highly Concentrated Potassium Chloride Injection, 10 mEq per 100 mL by Baxter: Recall - Mislabeled

Summary:

Highly Concentrated Potassium Chloride Injection 10 mEq per 100 mL by Baxter Recall Mislabeled

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

FDA Hearing Examines Impact of Anesthesia on Pediatric Patients

Friday, March 11, 2011

 

On March 10, the Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee met. The purpose of the meeting was to  (1) receive updates regarding neurodegenerative findings (findings related to degeneration in the nervous system) in juvenile animals exposed to anesthetic drugs, as well as results from human epidemiological studies using anesthesia in children (information related to studies of patterns and causes of disease); (2) discuss the relevance of these findings to pediatric patients and provide guidance for future preclinical and clinical studies; and (3) discuss the potential implications of these data upon the practice of pediatric anesthesia as well as the communication of the risk of sedative/anesthetic agents to prescribers and parents.

The multidisciplinary committee reviewed existing and in-progress clinical research before proceeding into discussion.  The discussion addressed the application of current research to clinical practice, future directions for research, the need for funding and collaboration, and communication of the current state of knowledge to parents.

Although the committee concluded that existing literature suggests there may be an issue of concern with sedation and anesthesia related neurotoxicity in pediatric patients, they said this information is insufficient to draw a definitive conclusion. The Committee emphasized that a large inbalance between studies performed on animals (90 percent) and studies performed on humans (10 percent) exists which makes it difficult to determine sufficient risk levels for sedative exposure in young children. 

The ASA submitted a joint statement in collaboration with the American Academy of Pediatrics (AAP) and the Society for Pediatric Anesthesia (SPA) that was read to the committee. The following is an excerpt from the statement; the entire statement can be viewed here

“ASA believes patient safety is the essence of anesthesiology.  We take very seriously the faith and trust that patients and their families place in us. For each child who requires anesthesia or sedation, anesthesiologists craft a carefully considered plan using the best, most current information to minimize discomfort and maximize safety. Unfortunately, the potential for harm exists despite anesthesiologists’ best efforts and current state of knowledge. We believe that we can best protect our patients from harm by continuing to pursue the very best science that informs our practices.”


 

 

« Back to Washington Alerts